Tearsheet

Phreesia (PHR)


Market Price (2/21/2026): $12.78 | Market Cap: $766.9 Mil
Sector: Health Care | Industry: Health Care Technology

Phreesia (PHR)


Market Price (2/21/2026): $12.78
Market Cap: $766.9 Mil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13%
Weak multi-year price returns
2Y Excs Rtn is -93%, 3Y Excs Rtn is -134%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -8.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.9%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%
  Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14%
2 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47%
  Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%
3 Low stock price volatility
Vol 12M is 48%
  Key risks
PHR key risks include [1] a history of cybersecurity incidents, Show more.
4 Megatrend and thematic drivers
Megatrends include Cloud Computing, Fintech & Digital Payments, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Show more.
  
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -13%
1 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13%
2 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -47%
3 Low stock price volatility
Vol 12M is 48%
4 Megatrend and thematic drivers
Megatrends include Cloud Computing, Fintech & Digital Payments, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Show more.
5 Weak multi-year price returns
2Y Excs Rtn is -93%, 3Y Excs Rtn is -134%
6 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -8.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -1.9%
7 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14%
8 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%
9 Key risks
PHR key risks include [1] a history of cybersecurity incidents, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Phreesia (PHR) stock has lost about 45% since 10/31/2025 because of the following key factors:

1. Revised Downward Organic Growth Guidance: Phreesia's management updated its fiscal year 2026 organic growth guidance to approximately 13%, a notable decrease from the prior fiscal year's 18%. This indicates a slowdown in the company's core business growth, which likely contributed to investor concerns regarding future performance.

2. Reduced Fiscal Year 2027 Subscription Revenue per Client Outlook: The company's outlook included a projected 7% decline in subscription revenue per client for fiscal year 2027, estimating it at $51.8K. This suggests potential pressure on the average revenue generated from each client, impacting future profitability.

Show more

Stock Movement Drivers

Fundamental Drivers

The -43.9% change in PHR stock from 10/31/2025 to 2/20/2026 was primarily driven by a -45.1% change in the company's P/S Multiple.
(LTM values as of)103120252202026Change
Stock Price ($)22.6412.71-43.9%
Change Contribution By: 
Total Revenues ($ Mil)4504633.0%
P/S Multiple3.01.6-45.1%
Shares Outstanding (Mil)6060-0.7%
Cumulative Contribution-43.9%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 2/20/2026
ReturnCorrelation
PHR-43.9% 
Market (SPY)1.1%30.4%
Sector (XLV)8.7%31.9%

Fundamental Drivers

The -52.9% change in PHR stock from 7/31/2025 to 2/20/2026 was primarily driven by a -55.0% change in the company's P/S Multiple.
(LTM values as of)73120252202026Change
Stock Price ($)26.9612.71-52.9%
Change Contribution By: 
Total Revenues ($ Mil)4354636.6%
P/S Multiple3.71.6-55.0%
Shares Outstanding (Mil)5960-1.8%
Cumulative Contribution-52.9%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 2/20/2026
ReturnCorrelation
PHR-52.9% 
Market (SPY)9.4%34.3%
Sector (XLV)20.8%25.8%

Fundamental Drivers

The -55.3% change in PHR stock from 1/31/2025 to 2/20/2026 was primarily driven by a -59.5% change in the company's P/S Multiple.
(LTM values as of)13120252202026Change
Stock Price ($)28.4612.71-55.3%
Change Contribution By: 
Total Revenues ($ Mil)40546314.3%
P/S Multiple4.11.6-59.5%
Shares Outstanding (Mil)5860-3.5%
Cumulative Contribution-55.3%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2025 to 2/20/2026
ReturnCorrelation
PHR-55.3% 
Market (SPY)15.6%40.2%
Sector (XLV)8.2%26.4%

Fundamental Drivers

The -66.1% change in PHR stock from 1/31/2023 to 2/20/2026 was primarily driven by a -78.1% change in the company's P/S Multiple.
(LTM values as of)13120232202026Change
Stock Price ($)37.4912.71-66.1%
Change Contribution By: 
Total Revenues ($ Mil)26246376.6%
P/S Multiple7.51.6-78.1%
Shares Outstanding (Mil)5360-12.3%
Cumulative Contribution-66.1%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2023 to 2/20/2026
ReturnCorrelation
PHR-66.1% 
Market (SPY)75.9%41.5%
Sector (XLV)23.1%28.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
PHR Return-23%-22%-28%9%-33%-26%-77%
Peers Return-32%-57%-2%-13%-22%-18%-84%
S&P 500 Return27%-19%24%23%16%0%83%

Monthly Win Rates [3]
PHR Win Rate42%42%42%50%25%0% 
Peers Win Rate37%30%50%43%37%20% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
PHR Max Drawdown-26%-67%-62%-22%-39%-30% 
Peers Max Drawdown-37%-62%-30%-44%-28%-27% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-1% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, DOCS, VEEV, AMWL, GDRX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/20/2026 (YTD)

How Low Can It Go

Unique KeyEventPHRS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-84.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven550.6%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-51.4%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven105.7%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven217 days148 days

Compare to TDOC, DOCS, VEEV, AMWL, GDRX

In The Past

Phreesia's stock fell -84.6% during the 2022 Inflation Shock from a high on 2/9/2021. A -84.6% loss requires a 550.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Phreesia (PHR)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.

AI Analysis | Feedback

  • Square for medical offices.

  • OpenTable for doctor's office check-ins.

  • TurboTax for healthcare check-ins.

AI Analysis | Feedback

Here are Phreesia's major products and services:
  • Patient Intake Platform: A comprehensive digital platform that streamlines patient registration, check-in, and data collection processes for healthcare providers.
  • Payment Processing: Facilitates secure and convenient collection of patient payments, including co-pays, deductibles, and outstanding balances.
  • Patient Engagement Solutions: Offers tools like appointment reminders, patient surveys, and digital forms to enhance communication and patient experience.
  • Clinical Support Solutions: Provides tools for collecting patient-reported data and integrating it into electronic health records to support clinical workflows.
  • Life Sciences Solutions: Enables pharmaceutical companies and clinical research organizations to identify, recruit, and engage patients for clinical trials.

AI Analysis | Feedback

Phreesia (PHR) primarily sells its healthcare technology solutions to other companies, specifically healthcare provider organizations.

Phreesia's public filings, such as its annual 10-K reports, do not disclose any individual customer or group of affiliated customers that account for 10% or more of its total revenue. This indicates a diverse and broad customer base rather than a reliance on a few "major" named customer companies. As such, no specific customer companies with their symbols can be listed as "major customers."

Therefore, while specific major customer names are not publicly available, Phreesia's customers are drawn from the following categories of healthcare organizations:

  • Physician Practices and Medical Groups: These customers range from small independent clinics to large multi-specialty physician organizations. Phreesia's platform helps them streamline patient intake, improve workflows, and manage patient engagement.
  • Hospitals and Health Systems: These are integrated networks that include multiple hospitals, outpatient clinics, and other healthcare facilities. Phreesia provides solutions to enhance patient experience and operational efficiency across their networks.
  • Other Healthcare Facilities: This broad category encompasses various specialized care providers such as urgent care centers, behavioral health clinics, dental practices, and ambulatory surgery centers, all benefiting from Phreesia's digital patient intake and engagement tools.

AI Analysis | Feedback

  • Amazon.com, Inc. (AMZN)
  • Stripe, Inc. (Private Company)
  • Fidelity National Information Services, Inc. (FIS)

AI Analysis | Feedback

Chaim Indig, Chief Executive Officer and Board Member

Since co-founding Phreesia in 2005, Chaim Indig has helped revolutionize the patient intake experience. Under his leadership, Phreesia has established a broad national footprint and developed strategic partnerships with large healthcare companies. Prior to founding Phreesia, he held key roles at Spotfire and OLAP@Work.

Balaji Gandhi, Chief Financial Officer

Balaji Gandhi leverages over 25 years of executive experience in overseeing Phreesia's financial operations and investor relations. Prior to joining Phreesia in 2019, he served as Chief Financial Officer of Madaket Inc., a cloud-based healthcare SaaS company. He also held leadership roles at companies including Press Ganey and Fresenius Medical Care, and spent more than a decade as an investment research analyst in the healthcare services market at firms such as Deutsche Bank and Oppenheimer & Co., Inc.

Evan Roberts, President, Provider Solutions

Evan Roberts co-founded Phreesia in 2005 and leads the company's efforts to bring value to its clients, overseeing ongoing operations and procedures. He previously served as Chief Technology Officer and as Vice President, Customer Solutions. Before co-founding Phreesia, Evan was a senior sales engineer at Spotfire, where he helped penetrate new markets and developed innovative applications.

David Linetsky, President of Network Solutions

David Linetsky is responsible for cultivating Phreesia's partnerships with life sciences companies, advocacy groups, government agencies, and other organizations. He has worked at Phreesia for more than a decade, holding key leadership roles including Vice President of Analytics and Insights, and Vice President of Finance. Prior to Phreesia, David worked in academia as a researcher and instructor in biotechnology, mathematics, and philosophy.

Allison Hoffman, General Counsel

As Phreesia's General Counsel, Allison Hoffman manages the company's Legal, Compliance, Risk, Privacy, and Security teams, bringing over 25 years of legal and people-management experience. Before Phreesia, she served as Chief Legal and Administrative Officer for Intersection, a digital technology company. She also oversaw the legal and human resources departments for Martha Stewart Living Omnimedia, culminating in oversight of the company's sale.

AI Analysis | Feedback

Here are the key risks to Phreesia's business:
  1. Cybersecurity Incidents and Data Privacy: Phreesia faces a significant risk from cybersecurity incidents and the need to maintain data privacy and security. The company has experienced such incidents in the past, including one impacting its ConnectOnCall product in 2024. Future incidents could disrupt business operations, harm the company's reputation, lead to economic loss, and expose them to legal penalties and liability, especially given the sensitive nature of the healthcare data they handle.
  2. Highly Competitive and Evolving Healthcare Industry: Phreesia operates in a very competitive industry characterized by rapidly changing technology standards, evolving regulatory requirements, and shifting client needs. Increased market saturation and competition from electronic health record (EHR) and practice management (PM) systems could negatively impact Phreesia's business and operating results.
  3. Regulatory Compliance with Healthcare and Data Privacy Laws: The company is subject to a complex and extensive framework of healthcare laws, as well as data privacy and security laws and regulations. Non-compliance with these laws could lead to substantial fines, penalties, lawsuits, adverse publicity, and a loss of customer trust, which would materially and adversely affect their business, prospects, financial condition, and results of operations.

AI Analysis | Feedback

The aggressive expansion and improvement of patient intake, engagement, and payment functionalities within major Electronic Health Record (EHR) platforms.

AI Analysis | Feedback

Phreesia (PHR) has an addressable market of approximately $24 billion across its main product and service segments in the U.S.. This market size includes the impact of the AccessOne acquisition.

  • Subscription-based revenue: approximately $6.3 billion (U.S.).
  • Payment solutions: approximately $9.1 billion (U.S.). This figure includes the implied provider financing market attributable to the AccessOne acquisition, which is expected to expand Phreesia's addressable market by roughly $6 billion.
  • Network solutions: approximately $8.2 billion (U.S.).

AI Analysis | Feedback

Phreesia (PHR) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:

  1. Growth in Average Healthcare Services Clients (AHSCs): Phreesia continues to expand its client base, with expectations to reach approximately 4,500 Average Healthcare Services Clients (AHSCs) in fiscal year 2026. This consistent growth in the number of clients directly contributes to overall revenue expansion.
  2. Increase in Total Revenue per AHSC through Client Monetization: The company is focused on increasing the revenue generated from each existing client. This involves the cross-selling of newer provider add-on solutions and securing larger initial solution bundles with new clients. Phreesia anticipates total revenue per AHSC to increase in fiscal 2026 compared to fiscal 2025.
  3. Expansion of Network Solutions: Phreesia's Network Solutions segment is gaining momentum and is a significant contributor to the acceleration of average revenue per client. This area is specifically highlighted by analysts as a growth driver.
  4. Strategic Acquisition of AccessOne: The acquisition of AccessOne is a notable driver, projected to add approximately $35 million in annualized revenue and expand Phreesia's total addressable market by about $6 billion. The transaction is expected to close in the third or early fourth quarter of Phreesia's fiscal year 2026.
  5. Launch and Growth of New and AI-driven Products: Phreesia is investing in and rolling out new solutions, including AI-driven products like Voice AI. These new offerings are designed to improve medication adherence and enhance the overall patient and provider experience, beginning to generate revenue and contributing to future growth.

AI Analysis | Feedback

Share Repurchases

Phreesia has a stock repurchase program in place, but it does not obligate the company to repurchase a specified number or dollar value of shares, and the program may be modified, suspended, or discontinued at any time. As of the available information, there is no indication of significant dollar amounts of share repurchases made over the last 3-5 years.

Share Issuance

  • As of March 7, 2025, Phreesia had 58,772,448 shares of common stock outstanding.
  • As of March 6, 2024, there were 56,387,472 shares of common stock outstanding.
  • As of March 17, 2023, there were 53,355,050 shares of common stock outstanding.

Outbound Investments

  • Phreesia announced in September 2025 a definitive agreement to acquire AccessOne Parent Holdings, Inc. for $160 million in cash. The transaction is expected to close in the third or early fourth quarter of Phreesia's fiscal year 2026.
  • In 2023, Phreesia acquired Access (likely Access eForms) and MediFind, both for undisclosed amounts.
  • In December 2021, Phreesia acquired Insignia Health for $35 million.

Capital Expenditures

  • Phreesia projects capital expenditures of $47 million for fiscal year 2026, $57 million for fiscal year 2027, $65 million for fiscal year 2028, $74 million for fiscal year 2029, and $84 million for fiscal year 2030, all estimated at 10% of revenue.
  • The company's strategic focus for capital allocation includes investing in scalable, high-value products that drive patient and provider outcomes, with artificial intelligence (AI) being a central area for future product development and operational enhancements.

Better Bets vs. Phreesia (PHR)

Trade Ideas

Select ideas related to PHR.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
VEEV_1302026_Monopoly_xInd_xCD_Getting_Cheaper01302026VEEVVeeva SystemsMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple
-14.6%-14.6%-15.7%
BIIB_1162026_Dip_Buyer_FCFYield01162026BIIBBiogenDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
19.5%19.5%0.0%
BMRN_1162026_Dip_Buyer_FCFYield01162026BMRNBioMarin PharmaceuticalDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
9.7%9.7%0.0%
DOCS_1162026_Dip_Buyer_High_CFO_Margins_ExInd_DE01162026DOCSDoximityDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
-39.4%-39.4%-40.1%
CORT_1022026_Dip_Buyer_High_CFO_Margins_ExInd_DE01022026CORTCorcept TherapeuticsDip BuyDB | CFO/Rev | Low D/EDip Buy with High Cash Flow Margins
Buying dips for companies with significant cash flows from operations and reasonable debt / market cap
4.6%4.6%-9.1%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

PHRTDOCDOCSVEEVAMWLGDRXMedian
NamePhreesia Teladoc .Doximity Veeva Sy.American.GoodRx  
Mkt Price12.714.7425.55180.315.452.479.08
Mkt Cap0.80.84.829.60.10.90.8
Rev LTM4632,5286383,080249801719
Op Inc LTM-9-179239859-1058337
FCF LTM351403071,378-66105123
FCF 3Y Avg-151532341,124-12496125
CFO LTM612933151,378-66180236
CFO 3Y Avg103052401,124-114163202

Growth & Margins

PHRTDOCDOCSVEEVAMWLGDRXMedian
NamePhreesia Teladoc .Doximity Veeva Sy.American.GoodRx  
Rev Chg LTM14.3%-2.4%15.9%16.0%-2.0%1.3%7.8%
Rev Chg 3Y Avg21.0%3.0%16.7%14.1%-3.4%0.4%8.5%
Rev Chg Q12.7%-2.2%9.8%16.0%-22.1%0.4%5.1%
QoQ Delta Rev Chg LTM3.0%-0.6%2.6%3.8%-5.9%0.1%1.4%
Op Mgn LTM-1.9%-7.1%37.4%27.9%-42.2%10.4%4.2%
Op Mgn 3Y Avg-21.7%-7.6%37.6%23.2%-75.5%4.4%-1.6%
QoQ Delta Op Mgn LTM4.0%0.2%-2.3%1.0%4.1%-0.7%0.6%
CFO/Rev LTM13.3%11.6%49.5%44.7%-26.5%22.5%17.9%
CFO/Rev 3Y Avg1.0%11.9%42.8%41.8%-44.6%21.0%16.4%
FCF/Rev LTM7.6%5.5%48.2%44.7%-26.5%13.1%10.3%
FCF/Rev 3Y Avg-5.3%6.0%41.6%41.8%-48.6%12.4%9.2%

Valuation

PHRTDOCDOCSVEEVAMWLGDRXMedian
NamePhreesia Teladoc .Doximity Veeva Sy.American.GoodRx  
Mkt Cap0.80.84.829.60.10.90.8
P/S1.60.37.59.60.41.11.4
P/EBIT-337.3-3.720.134.4-0.88.84.0
P/E-141.8-3.820.034.4-0.927.09.5
P/CFO12.42.915.221.5-1.44.88.6
Total Yield-0.7%-26.7%5.0%2.9%-107.0%3.7%1.1%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-0.9%9.2%3.0%3.3%-82.6%6.5%3.2%
D/E0.01.20.00.00.10.60.0
Net D/E-0.10.4-0.2-0.2-2.00.3-0.1

Returns

PHRTDOCDOCSVEEVAMWLGDRXMedian
NamePhreesia Teladoc .Doximity Veeva Sy.American.GoodRx  
1M Rtn-18.6%-23.1%-35.9%-17.9%20.0%-4.3%-18.3%
3M Rtn-36.6%-31.9%-49.3%-26.1%41.9%-8.9%-29.0%
6M Rtn-57.3%-38.3%-62.3%-38.0%-23.8%-45.8%-42.1%
12M Rtn-55.3%-62.6%-65.9%-21.2%-54.8%-49.2%-55.1%
3Y Rtn-64.0%-83.4%-23.9%6.3%-92.4%-52.7%-58.3%
1M Excs Rtn-19.1%-23.5%-36.4%-18.4%19.6%-4.8%-18.8%
3M Excs Rtn-39.6%-36.7%-50.5%-38.5%31.2%-15.9%-37.6%
6M Excs Rtn-62.1%-42.4%-68.3%-44.5%-28.5%-51.5%-48.0%
12M Excs Rtn-69.6%-78.0%-79.1%-33.8%-68.8%-64.3%-69.2%
3Y Excs Rtn-133.8%-151.5%-90.0%-62.2%-159.7%-120.0%-126.9%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Technology solutions segment356281213149125
Total356281213149125


Price Behavior

Price Behavior
Market Price$12.71 
Market Cap ($ Bil)0.8 
First Trading Date07/18/2019 
Distance from 52W High-61.0% 
   50 Days200 Days
DMA Price$15.17$22.69
DMA Trenddowndown
Distance from DMA-16.2%-44.0%
 3M1YR
Volatility58.4%48.3%
Downside Capture428.13199.81
Upside Capture61.3691.15
Correlation (SPY)24.4%39.6%
PHR Betas & Captures as of 1/31/2026

 1M2M3M6M1Y3Y
Beta2.081.631.711.671.021.50
Up Beta1.981.441.751.910.741.10
Down Beta0.62-1.17-0.830.880.691.24
Up Capture36%107%120%67%102%388%
Bmk +ve Days11223471142430
Stock +ve Days7202858121369
Down Capture613%518%356%255%146%112%
Bmk -ve Days9192754109321
Stock -ve Days13213367126375

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PHR
PHR-56.3%48.4%-1.55-
Sector ETF (XLV)8.6%17.3%0.3226.5%
Equity (SPY)13.5%19.4%0.5339.8%
Gold (GLD)74.5%25.6%2.15-0.9%
Commodities (DBC)7.2%16.9%0.2510.9%
Real Estate (VNQ)7.1%16.7%0.2423.9%
Bitcoin (BTCUSD)-30.6%44.9%-0.6818.8%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with PHR
PHR-30.3%59.2%-0.37-
Sector ETF (XLV)7.6%14.5%0.3432.1%
Equity (SPY)13.4%17.0%0.6245.5%
Gold (GLD)22.6%17.1%1.086.0%
Commodities (DBC)10.9%19.0%0.465.7%
Real Estate (VNQ)5.0%18.8%0.1737.5%
Bitcoin (BTCUSD)7.2%57.1%0.3523.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date1302026
Short Interest: Shares Quantity3.2 Mil
Short Interest: % Change Since 11520264.4%
Average Daily Volume1.2 Mil
Days-to-Cover Short Interest2.7 days
Basic Shares Quantity60.0 Mil
Short % of Basic Shares5.4%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
12/8/2025-23.3%-17.0%-16.0%
9/4/2025-9.9%-18.4%-25.4%
5/28/2025-6.6%3.3%12.0%
3/12/20256.9%21.8%0.8%
12/9/202411.6%18.5%23.3%
9/4/20246.3%-3.5%-8.7%
5/30/2024-11.2%-7.3%-3.0%
3/14/20244.8%4.0%0.4%
...
SUMMARY STATS   
# Positive101213
# Negative1198
Median Positive6.9%13.3%8.5%
Median Negative-9.9%-8.4%-19.1%
Max Positive21.2%35.7%51.3%
Max Negative-23.3%-33.5%-40.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
10/31/202512/09/202510-Q
07/31/202509/05/202510-Q
04/30/202505/28/202510-Q
01/31/202503/13/202510-K
10/31/202412/09/202410-Q
07/31/202409/05/202410-Q
04/30/202405/31/202410-Q
01/31/202403/15/202410-K
10/31/202312/06/202310-Q
07/31/202309/07/202310-Q
04/30/202306/01/202310-Q
01/31/202303/23/202310-K
10/31/202212/09/202210-Q
07/31/202209/08/202210-Q
04/30/202206/03/202210-Q
01/31/202203/31/202210-K

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Linetsky, DavidPresident, Network SolutionsSpouseSell1219202516.49941,550161,384Form
2Hui, YvonnePrincipal Accounting OfficerDirectSell1219202516.254266,922486,038Form
3Gandhi, BalajiChief Financial OfficerDirectSell1021202522.3688519,7902,196,764Form
4Hoffman, Allison CGeneral Counsel & SecretaryDirectSell1021202522.361,24127,7503,035,242Form
5Indig, ChaimChief Executive OfficerDirectSell1021202522.363,16370,72828,009,818Form